The biotech firm’s shareholder approval opens the door for the US drugmaker to enter the booming weight loss drug market.

Eli Lilly and Novo Nordisk have agreed to sell their weight loss drugs, Wegovy and Zepbound, through the new TrumpRx ...

Scientists have known that obesity and metabolic dysfunction can make cancers more aggressive. Tumors thrive in bodies ...

This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss ...

WeightWatchers intends to offer Novo Nordisk’s pill version of Wegovy if it makes its US debut next year following potential ...

WeightWatchers' CEO said on Wednesday it planned to offer Novo Nordisk's much-anticipated Wegovy in pill form if it is ...

How Ozempic Is Changing Thanksgiving According to the independent research and polling source KFF, one in eight Americans reported taking a GLP-1 receptor agonist ...

(Reuters) -Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing the U.S.

Mangoceuticals' partnership with Lilly and Novo allows the telehealth company to keep selling Zepbound and Wegovy. The telehealth company said Thursday's partnership announcement comes in conjunction ...

WeightWatchers to sell oral form of Wegovy if it launches next year; Dr. Richard Pazdur to head FDA’s CDER; anti-abortion group invests $80 million in campaign for midterm elections.

Novo Nordisk maintains strong growth prospects, driven by obesity treatment market expansion. See why NVO stock is a strong ...